Insurance, Policy, Knowledge Level and Epidemiology As Factors Affecting Demand And Supply of Pharmaceutical Product

Authors

  • Noor Cahaya Universitas Lambung Mangkurat
  • Hananditia Rachma Pramestutie Departemen Farmasi, Fakultas Kedokteran, Universitas Brawijaya
  • Anita Kumala Hati Departemen farmasi, Fakultas Kesehatan, Universitas Ngudi Waluyo
  • Eka Kartika Untari Departemen Farmasi, Fakultas Kedokteran, Universitas Tanjung Pura
  • Pinasti Utami Departemen farmasi Klinik dan Farmakologi, Fakultas Kedokteran dan Ilmu Kesehatan, Universitas Muhamadiyah Yogyakarta

DOI:

https://doi.org/10.21776/ub.pji.2022.007.02.2

Keywords:

demand and supply, policy, insurance, pharmaceutical product

Abstract

Fulfillment of drug availability is always a challenge from year to year and is determined by supply
and demand issues for pharmaceutical drugs. Good management of drugs and pharmaceutical supplies is
important in health services. This is related to the quality of health services and the efficiency and
effectiveness of the budget. This review study aims to examine the factors that influence drug supply and
demand simultaneously with a different perspective from other studies, namely, the focus is to
simultaneously discuss the effects of health insurance financing schemes, registration regulations for
pharmaceutical products and imports of pharmaceutical products, the level of pharmacist knowledge,
changes in disease patterns, disasters, and wars on drug supply and demand. The research design that was
used in this study is a narrative review. The data sources that were used are PubMed, Science Direct,
Scopus, and Google Scholar. The inclusion criteria in this study are all research related to the demand for
pharmaceutical supplies and drugsthat will be reviewed in the study, either in the form of original research,
reviews, or reports. The results obtained articles consisting of 8 articles related to health insurance
financing, 6 articles related to registration regulation of pharmaceutical products and import of
pharmaceutical products, 5 articles related to pharmacist knowledge level, 3 articles related to changes in
disease patterns, and 3 articles related to disasters and wars. Based on the 25 articles that were used as data
in this study, it was found that the factors that influence the supply and demand of pharmaceutical supplies
are health insurance financing, regulation of registration drug processes and imports of pharmaceutical
products, level of knowledge of pharmacists as pharmaceutical service providers, changes in disease
patterns, disasters, politics, and war.

References

Niken A. Tata Kelola Obat di Era Sistem Jaminan Kesehatan Nasional (JKN). J Antikorupsi. 3(2):231–43.

Shukar S, Zahoor F, Hayat K, Saeed A, Gillani AH, Omer S, et al. Drug Shortage: Causes, Impact, and Mitigation Strategies. Front Pharmacol. 2021 Jul 9;12:693426.

Kanda MK, Iravo MA. Access Factors Affecting Supply Chain Efficiency of Medical Supplies in public Health Centers in Kenya: A Case Study of Public Health Centers in Elgeyo Marakwet Count. Int J Acad Res Account Finance Manag Sci. 2015 Jun 19;5(2):Pages 32-41.

AL-hawawsheh B. Impact of Pharmaceutical Supply Chain Factors Effectiveness on Drug Availability in Public Hospitals. J Manag POLICIES Pract [Internet]. 2019 [cited 2021 Nov 26];7(2). Available from: http://jmppnet.com/vol-7-no-2-december-2019-abstract-3-jmpp

Carey C. Sharing the burden of subsidization: Evidence on pass-through from a subsidy revision in Medicare Part D. J Public Econ. 2021;198:104401.

De Weerdt J, Dercon S. Risk-sharing networks and insurance against illness. J Dev Econ. 2006;81(2):337–56.

Flores G, Krishnakumar J, O’Donnell O, van Doorslaer E. Coping with health-care costs: implications for the measurement of catastrophic expenditures and poverty. Health Econ. 2008 Dec 1;17(12):1393–412.

Sparrow R, Suryahadi A, Widyanti W. Social health insurance for the poor: Targeting and impact of Indonesia’s Askeskin programme. Soc Sci Med. 2013;96:264–71.

Arrow K. Agency and the welfare economics of medical care. Am Econ Rev. 1963;53(5):941973.

Feldstein M. The welfare loss of excess health insurance. J Polit Econ. 1973;81(March–April):251–80.

Zeckhauser R. Medical insurance: a case study of the tradeoff between risk spreading and the appropriate incentives. J Econ Theor. 1970;2:10–26.

Ponzo M, Scoppa V. Does demand for health services depend on cost-sharing? Evidence from Italy. Econ Model. 2021;103(October 2020):105599.

Rättö H, Kurko T, Martikainen JE, Aaltonen K. The impact of a co-payment increase on the consumption of type 2 antidiabetics – A nationwide interrupted time series analysis. Health Policy. 2021;125(9):1166–72.

Kirsch M, Montgomery JR, Hu HM, Englesbe M, Hallstrom B, Brummett CM, et al. Association between insurance cost-sharing subsidy and postoperative opioid prescription refills among Medicare patients. Surg U S. 2020;168(2):244–52.

Look KA, Arora P. Effects of the Affordable Care Act’s young adult insurance expansion on prescription drug insurance coverage, utilization, and expenditures. Res Soc Adm Pharm. 2016;12(5):682–98.

Ghosh A, Simon K, Sommers BD. The Effect of Health Insurance on Prescription Drug Use Among Low-Income Adults:Evidence from Recent Medicaid Expansions. J Health Econ. 2019;63:64–80.

Fiorio C V., Siciliani L. Co-payments and the demand for pharmaceuticals: Evidence from Italy. Econ Model. 2010;27(4):835–41.

Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007 Jul 4;298(1):61–9.

Piette JD, Heisler M, Wagner TH. Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. Am J Public Health. 2004 Oct;94(10):1782–7.

Kiil A, Houlberg K. How does copayment for health care services affect demand, health and redistribution? A systematic review of the empirical evidence from 1990 to 2011. Eur J Health Econ. 2014;15(8):813–28.

Luiza VL, Chaves LA, Silva RM, Emmerick ICM, Chaves GC, Fonseca de Araújo SC, et al. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Cochrane Database Syst Rev. 2015 May 8;2015(5):CD007017–CD007017.

Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, et al. Pharmacy Benefits and the Use of Drugs by the Chronically Ill. JAMA. 2004 May 19;291(19):2344–50.

Mahoney J. J. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 Suppl):170–6.

Karter AJ, Parker MM, Solomon MD, Lyles CR, Adams AS, Moffet HH, et al. Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE). Health Serv Res. 2017/05/05 ed. 2018 Apr;53(2):1227–47.

Ellis RP, McGuire TG. Supply-side and demand-side cost sharing in health care. J Econ Perspect J Am Econ Assoc. 1993;7(4):135–51.

Organisation for Economic Co-operation and Development. OECD Health Data: a comparative analysis of 30 countries. Paris; 2007.

African S. Regulatory harmonization. WHO Drug Inf. 2010;24(1):6–20.

Kaplan WA, Laing R. Paying for pharmaceutical registration in developing countries. Health Policy Plan. 2003;18(3):237–48.

Ratanawijitrasin S, Soumerai SB, Weerasuriya K. Do national medicinal drug policies and essential drug programs improve drug use?: A review of experiences in developing countries. Soc Sci Med. 2001;53(7):831–44.

Muia MD. Factors Affecting Consistency in Supply of Pharmaceutical Products in Government Hospitals in Kenya : A Case Study of Maragua District Hospital. 2013;3(13):21–53.

Poh J, Tam KT. Registration of similar biological products – Singapore’s approach. Biologicals. 2011 Sep;39(5):343–5.

Bhutta TI, Balchin C. Assessing the impact of a regulatory intervention in Pakistan. Soc Sci Med. 1996 Apr 1;42(8):1195–202.

Narsai K, Williams A, Mantel-Teeuwisse AK. Impact of regulatory requirements on medicine registration in African countries - perceptions and experiences of pharmaceutical companies in South Africa. South Med Rev. 2012;5(1):31–7.

Sun Q, Santoro MA, Meng Q, Liu C, Eggleston K. Pharmaceutical policy in China. Health Aff (Millwood). 2008;27(4):1042–50.

AL-hawawsheh B. Impact of Pharmaceutical Supply Chain Factors Effectiveness on Drug Availability in Public Hospitals. J Manag Policies Pract. 2019;7(2).

Waluyo YW, Athiyah U, Rochmah TN. Analisis Faktor yang Mempengaruhi Pengelolaan Obat Publik di Instalasi Farmasi Kabupaten ( Studi di Papua Wilayah Selatan ). J Ilmu Kefarmasian Indones. 2015;13(1):94–101.

Umi Athiyah , Catur D. Setiawan , Gesnita Nugraheni, Elida Zairina, Wahyu Utami AH. Assessment of pharmacists’ knowledge, attitude and practice in chain community pharmacies towards their current function and performance in Indonesia. Pharm Pract. 2019;17(3):1–7.

Herlinawati H, Lestari SA. Hubungan Tingkat Pengetahuan Dan Pendidikan Dengan Pengelolaan Obat Di Puskesmas. J Kesehat. 2020;11(1):1426–33.

Aryani AF, Kusuma AM, Galistiani GF. HUBUNGAN TINGKAT PENGETAHUAN PENGELOLA OBAT TERHADAP PENGELOLAAN OBAT DI PUSKESMAS. J Manaj DAN PELAYANAN Farm J Manag Pharm Pract. 2016 Dec 30;6(4):303.

Hariadini AL, Ishmah N, Pramestutie HR. Correlation between the level of knowledge of drug managers and drug management in several primary health centres in Malang regency. Pharm Educ. 2021 Jul 28;61–6.

Wirth T. Globalization and infectious diseases. Biodivers Evol. 2018;(3):123–37.

Bappenas. Kajian Sektor Kesehatan Penyediaan Obat, Vaksin dan Alat Kesehatan. 2019. 1–50 p.

Robertson J, Macé C, Forte G, de Joncheere K, Beran D. Medicines availability for non-communicable diseases: The case for standardized monitoring. Glob Health. 2015;11(18):1–6.

Kristina SA, Mardea NA, Putri MF, Khairunnisa FF. Medicines ’ availability and affordability for non - communicable diseases in Yogyakarta , Indonesia. 2020;25(4):2105–12.

Elias MA, Pati MK, Aivalli P, Srinath B, Munegowda C, Shroff ZC, et al. Preparedness for delivering noncommunicable disease services in primary care: Access to medicines for diabetes and hypertension in a district in south India. BMJ Glob Health. 2017;2:1–12.

Burry LD, Barletta JF, Williamson D, Kanji S. It Takes a Village...Contending With Drug Shortages During Disasters. Chest. 2020;158(6):2414–24.

Tirivangani T, Alpo B, Kibuule D, Gaeseb J, Adenuga BA. Impact of COVID-19 pandemic on pharmaceutical systems and supply chain – a phenomenological study. Explor Res Clin Soc Pharm. 2021;2:100037.

Wu H liang, Huang J, Zhang CJP, He Z, Ming WK. Facemask shortage and the novel coronavirus disease (COVID-19) outbreak: Reflections on public health measures. EClinicalMedicine. 2020;21:1–7.

Okeagu CN, Reed DS, Lu S, Colontonio MM, Rezayev A. Principle of Supply Chain managamenet in the time of crisis. Best Pract Res Clin Anaesthesiol. 2021;35:369–76.

Alshakka M, Mohamed Ibrahim MI, Bahattab A, Badulla WFS, Shankar PR. An insight into the pharmaceutical sector in Yemen during conflict: challenges and recommendations. Med Confl Surviv. 2020;1–18.

Downloads

Published

2022-06-30

Issue

Vol. 7 No. 2 (2022)

Section

Articles

License

Copyright (c) 2022 Pharmaceutical Journal of Indonesia Creative Commons Licence
This work is licensed under a Creative Commons Attribution 4.0 International License